The Journal of Bone and Joint Surgery (American). 2007;89:500-511.
doi:10.2106/JBJS.F.00127
© 2007 The Journal of Bone and Joint Surgery, Inc.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the activities for this article:
 Trauma Test 17: Spring 2007 (publication date May 15, 2007; expiration date...
Basic Science Test 9: Spring 2007 (publication date May 15, 2007; expiratio...
CME 1: January, February, March 2007 (publication date April 5, 2007; expir...
Adult Hip Reconstruction Test 24: Spring 2007 (publication date May 15, 200...
Right arrow [Supplementary Material]
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simon, A. M.
Right arrow Articles by O'Connor, J. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Simon, A. M.
Right arrow Articles by O'Connor, J. P.
Related Collections
Right arrow Adult Trauma
Right arrow Basic Science
Right arrow Adult Hip
Right arrow Adult Knee
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?

Dose and Time-Dependent Effects of Cyclooxygenase-2 Inhibition on Fracture-Healing

Ann Marie Simon, BS1 and J. Patrick O'Connor, PhD1

1 Department of Orthopaedics, UMDNJ-New Jersey Medical School, MSB G580/ORTHO, 185 South Orange Avenue, Newark, NJ 07103. E-mail address for J.P. O'Connor: oconnojp{at}umdnj.edu

Investigation performed at the Department of Orthopaedics, UMDNJ-New Jersey Medical School, Newark, New Jersey

Disclosure: In support of their research for or preparation of this work, one or more of the authors received, in any one year, outside funding or grants in excess of $10,000 from the Arthritis Foundation and the Orthopaedic Research and Education Foundation. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member of their immediate families, are affiliated or associated.

A commentary is available with the electronic versions of this article, on our web site (www.jbjs.org) and on our quarterly CD-ROM (call our subscription department, at 781-449-9780, to order the CD-ROM).

Background: Fracture-healing is impaired in mice lacking a functional cyclooxygenase-2 (COX-2) gene or in rats continuously treated with COX-2 inhibitors. These observations indicate that COX-2 is a critical regulator of fracture repair. Nonsteroidal anti-inflammatory drugs are commonly used to treat pain associated with musculoskeletal trauma and disease. Nonsteroidal anti-inflammatory drugs inhibit COX-2 function and in so doing can impair fracture-healing. The goal of the present study was to determine how variations in nonsteroidal anti-inflammatory drug therapy ultimately affect fracture-healing.

Methods: Closed femoral fractures were made in female Sprague-Dawley rats. The rats were treated with different doses of celecoxib (a COX-2-selective nonsteroidal anti-inflammatory drug) or were treated for different periods before or after fracture with celecoxib. Eight weeks after the fracture, healing was assessed with radiography and destructive torsional mechanical testing. The effect of celecoxib treatment on fracture callus prostaglandin E2 and F2{alpha} levels was determined as a measure of cyclooxygenase activity.

Results: Celecoxib doses as small as 2 mg/kg/day reduced fracture callus mechanical properties and caused a significant increase in the proportion of nonunions. Similarly, treatment with celecoxib at a dose of 4 mg/kg/day for just five days reduced fracture callus mechanical properties and significantly increased the proportion of nonunions. Conversely, celecoxib therapy prior to fracture or initiated fourteen days after fracture did not significantly increase the proportion of nonunions. Celecoxib treatment at a dose of 4 mg/kg/day reduced fracture callus prostaglandin E2 and F2{alpha} levels by >60%.

Conclusions: COX-2-selective nonsteroidal anti-inflammatory drug therapy during the early stages of fracture repair significantly reduced fracture callus mechanical properties at later stages of healing and increased the proportion of nonunions in this animal model.

Clinical Relevance: Celecoxib therapy in the therapeutic range used by humans significantly impaired fracture-healing if administered during the first two weeks after a fracture in this animal model. However, celecoxib therapy prior to fracture or after the early stages of fracture-healing did not impede healing. These observations indicate that nonsteroidal anti-inflammatory drug therapy during the early stages of fracture-healing probably should be avoided.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
Z. A. Radi
Pathophysiology of Cyclooxygenase Inhibition in Animal Models
Toxicol Pathol, January 1, 2009; 37(1): 34 - 46.
[Abstract] [Full Text] [PDF]